Marina Biotech (MRNA) Posts Wider than Expected Q1 Loss

Marina Biotech, Inc. (Nasdaq: MRNA) reported Q1 loss of ($0.12), $0.01 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $214 million versus the consensus estimate of $150 thousand.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• UBS Reiterates Neutral Rating on Moderna (MRNA)
• A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
• Moderna (MRNA) spreader of 1K contracts of September 25 weekly 157.50 and 165 calls as share price up 10.5%